25.1 C
New York
Tuesday, June 2, 2026

Tag: PR

Nutrition Business Journal Releases 2026 Supplement Business Report: U.S. Market Surges Toward $100 Billion Milestone

Nutrition Business Journal Releases 2026 Supplement Business Report, Comprehensive Industry Analysis Driving Growth in Dietary Supplements

CROSSJECT met à disposition les réponses aux questions de ses actionnaires préalablement à son Assemblée Générale

CROSSJECT met à disposition les réponses aux questions de ses actionnaires préalablement à son Assemblée Générale

New Transit App Go NYC Launches, Bringing Subway, Bus, and Regional Rail Together

NEW YORK, June 2, 2026 /PRNewswire-HISPANIC PR WIRE/ -- Go NYC is a new transit app built around the way New Yorkers actually move...

Arelion expands Conflict-Free Channel Program in Mexico

STOCKHOLM, June 2, 2026 /PRNewswire/ -- Arelion today announced the expansion of its Conflict-Free Channel Program in Mexico, leveraging its extensive network to support...

Greenland Mines Appoints WSP Denmark to Continue Environmental Baseline Work at the Sarfartoq Rare Earth Project

CHARLOTTE, N.C., June 2, 2026 /PRNewswire/ -- Greenland Mines Ltd ("Greenland Mines" or the "Company") (Nasdaq: GRML) today announced that it has engaged WSP...

Cyware Expands Threat Intelligence Suite with new Digital Risk Protection

New Integrated DRP Capabilities powered by SOCRadar Combine External Visibility with Live Threat Context to Trigger Automated Defensive Actions in Real TimeNEW YORK, June...

1win Signs Full Tundra Roster Under the 1win Team Banner

BELGRADE, Serbia, June 02, 2026 (GLOBE NEWSWIRE) -- International crypto entertainment platform 1win has officially announced the signing of the full Tundra Esports Dota 2 roster. Effective June 1, professional players Pure, bzm, 33, Ari, and Whitemon compete under the 1win Team tag. Alongside the players, coach MoonMeander, esports analyst degaz, team manager Jamba, and sports director SweetyPotz are joining the organization.

VEON Closes USD 1.4 Billion Bond Offering, Refinancing 2027 Notes Ahead of Schedule

Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.

WeRide, Uber and AVOMO Bring Robotaxis to Madrid

WeRide and Uber announced plans to launch Spain’s first commercial Robotaxi pilot in Madrid, marking their first joint entry into the European market.

EVADAV TRAFFIC GROUP Announces Expanded Divisions to Accelerate Global Growth

EVADAV TRAFFIC GROUP restructures into four divisions to accelerate growth across performance marketing, media buying, and mobile apps.

Equinor ASA: Tilbakekjøp av egne aksjer – andre transje for 2026

Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2026.

The new version of the Articles of Association of UAB Urbo bankas was registered

Urbo bankas UAB (hereinafter - “the Bank”), company code 112027077, address: Konstitucijos pr.18B, Vilnius.

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPR